Inactivation of Ybx1 by pIpC injections after engraftment of leukemic cells in primary recipient mice resulted in a delay of leukemia onset (Fig. 2E, Supplementary Fig. 3E) and prolongation of survival (median survival of MA9-Ybx1 + /+ 73 days; MA9-Ybx1−/− 91.5 days; p = 0.0121*) (Fig. 2F). Here, YBX1 is linked to leukemia.